Trial Profile
A Clinical Study Of Enadenotucirev Administered by Sub-Acute Fractionated Intravenous Injection: Dose Escalation in Metastatic Epithelial Solid Tumours and Randomised Controlled Trial in Metastatic Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Jan 2023
Price :
$35
*
At a glance
- Drugs Enadenotucirev (Primary)
- Indications Bladder cancer; Carcinoma; Colorectal cancer; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Urogenital cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms EVOLVE
- Sponsors Akamis Bio; PsiOxus Therapeutics
- 05 Jan 2023 According to an Akamis Bio media release, PsiOxus Therapeutics has changed its name to Akamis Bio.
- 20 Mar 2018 Status changed from active, no longer recruiting to completed.
- 11 Oct 2016 Results assessing the pattern of enadenotucirev delivery within tumors in patients with colon, lung, bladder and renal carcinoma (n=17) presented at the 41st European Society for Medical Oncology Congress.